Northwest Biotherapeutics Inc (NWBO)
NWBO is quoted over the counter, not listed on an exchange. Northwest Biotherapeutics Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | NWBO, quoted over the counter |
| SEC CIK | 0001072379 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Bethesda, MD |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for at least one year from the date of this filing." | 10-Q 2026-11-13 |
| Cash and burn | $595K cash; operating cash flow -$12.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,811,970,770 (2026-11-10); 1,540,682,082 a year earlier; 1,153,846,907 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2025-11-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Cherry Bekaert LLP, Nashville, Tennessee, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $807K | -$9.2M | -$7.2M | $595K | $52.0M | $2.2M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $494K | -$3.1M | -$12.5M | $1.8M | $59.4M | $1.5M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $672K | $1.4M | -$14.8M | $3.0M | $60.0M | $1.4M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $200K | -$26.8M | -$13.9M | $4.6M | $72.2M | $937K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $131K | -$15.4M | -$6.7M | $4.3M | $64.7M | $1.1M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $375K | -$19.3M | -$9.4M | $2.8M | $64.1M | $1.5M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $231K | -$28.2M | -$20.2M | $2.2M | $62.7M | $1.4M | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $357K | -$19.4M | -$8.2M | $2.9M | $53.3M | $1.6M | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-31 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy | DEF 14A | 2025-11-28 |
Source: SEC EDGAR submissions feed, 804 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier